Sutro Biopharma
STRO
117 hedge funds and large institutions have $302M invested in Sutro Biopharma in 2024 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 49 increasing their positions, 32 reducing their positions, and 17 closing their positions.
286% more call options, than puts
Call options by funds: $54K | Put options by funds: $14K
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
53% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 32
26% more capital invested
Capital invested by funds: $240M → $302M (+$62M)
18% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 17
3% more funds holding
Funds holding: 114 → 117 (+3)
0.61% less ownership
Funds ownership: 9.17% → 8.55% (-0.61%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$18.1M |
| 2 |
Millennium Management
New York
|
+$14.1M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$3.47M |
| 4 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$3.29M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$3.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$14.4M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$14.3M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$11.9M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.9M |
| 5 |
Vontobel Holding
Zurich,
Switzerland
|
-$2.77M |
STRO Hedge Fund Activity: Q1 2024 in Review
117 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q1 2024, worth a combined $302M — up 26% from $240M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new STRO positions and 17 closed out — a net gain of 3 holders — while 49 added to existing stakes and 32 trimmed.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $18.1M. The largest seller was BVF Inc, exiting entirely with an estimated $14.4M sold.
- 117 institutional investors held Sutro Biopharma (STRO) as of Q1 2024, up from 114 in Q4 2023.
- Funds reported $302M of Sutro Biopharma stock for Q1 2024, up 26% quarter-over-quarter.
- 20 funds opened new Sutro Biopharma positions in Q1 2024 and 17 closed out, a net change of +3 holders.
- The largest Sutro Biopharma buyer in Q1 2024 was MPM BioImpact, an estimated $18.1M added.
- The largest Sutro Biopharma seller in Q1 2024 was BVF Inc, an estimated $14.4M sold.
Based on aggregated 13F filings for Q1 2024.